Live tape
Top 8, mentions 7d7,047NVDA1,209 mentions▲ +0.10GOOGL1,023 mentions▲ +0.04AVGO1,014 mentions▲ +0.05NKE996 mentions+0.02LULU941 mentions▲ +0.03TSLA809 mentions▲ +0.06META563 mentions▲ +0.05MSFT492 mentions▲ +0.07

Equity · Healthcare

CCCC

C4 Therapeutics, Inc. · NasdaqGS

$3.76 +0.40% 1D Finazon · prior-day close · Sep 4, 2026
Price · Chart
Our own end-of-day closes 61 sessions
$5.0 $3.0 10 Jun 4 Sep

The line runs $3.87 on 10 June through $3.76 on 4 September, on a scale from $3.0 to $5.0. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of CCCC over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $3.87 on 10 June 2026 through $3.76 on 4 September 2026.

Market cap $462.0M
52-week range $1.70 – $4.66
Avg volume 267.3K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026

CCCC insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 10 Jul 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 4

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
10 Jul 2026 REYNO LEONARD Chief Medical Officer Option exercise 15,325
10 Jul 2026 REYNO LEONARD Chief Medical Officer Tax withheld 7,397 $30K
01 Jul 2026 Anderson Kenneth Carl Director Award 2,650 $12K
01 Jul 2026 GROGAN DONNA ROY Director Award 3,341 $14K

CCCC reported financials

SEC EDGAR XBRL

CCCC reported revenue of $35.9M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$105.0M.

Figure Reported Period
Revenue $35.9M 31 Dec 2025 fiscal year
Net income −$105.0M 31 Dec 2025 fiscal year
Diluted EPS −$1.27 31 Dec 2025 fiscal year
Total assets $359.4M 30 Jun 2026 at period end
Total equity $247.3M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

CCCC earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.18 $7M
31 Mar 2026 Q1 2026 $-0.20 $6M
31 Dec 2025 FY 2025 $-1.27 $36M
30 Sep 2025 Q3 2025 $-0.44 $11M
30 Jun 2025 Q2 2025 $-0.37 $6M
31 Mar 2025 Q1 2025 $-0.37 $7M
31 Dec 2024 FY 2024 $-1.52 $36M
30 Sep 2024 Q1 2023 $-0.35 $15M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

CCCC institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a CCCC position for the quarter ended 30 Jun 2026 — a combined $54.2M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Citadel Advisors Added +66.8% shares 4,187,580 $19.6M
Two Sigma Investments Held (±25%) +14.3% shares 3,469,707 $16.2M
D. E. Shaw & Co. Added +64.2% shares 1,740,989 $8.1M
Renaissance Technologies Trimmed −51.7% shares 1,189,828 $5.6M
Man Group Added +59.3% shares 408,648 $1.9M
Marshall Wace Added +46.0% shares 227,003 $1.1M
Millennium Management Trimmed −84.5% shares 215,386 $1.0M
Point72 Asset Management Held (±25%) +2.9% shares 173,965 $812K

Source: SEC EDGAR 13F filings

CCCC fails-to-deliver

SEC CNS data

On 11 Aug 2026, 16 shares of CCCC failed to deliver (about $58) — the latest of 4 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
11 Aug 2026 16 $58 <0.001%
10 Aug 2026 1,955 $7K 0.002%
07 Aug 2026 1,976 $7K 0.002%
06 Aug 2026 5,736 $21K 0.005%
04 Aug 2026 1,204 $4K 0.001%
03 Aug 2026 12,660 $44K 0.010%

Source: SEC fails-to-deliver (CNS) data